Eye injection aims to clear fluid in chronic vision disorder
NCT ID NCT07681167
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This trial investigates whether faricimab, an eye injection, can help people with chronic central serous chorioretinopathy (CSCR), a condition where fluid builds up under the retina and can cause vision loss. The study includes 50 adults with persistent fluid for at least three months. Participants receive either faricimab or a sham injection over three months, with the main goal of seeing if the drug can completely resolve the fluid.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- faricimab
- What this could lead to
- If successful, faricimab could offer a new treatment option for people with chronic central serous chorioretinopathy, potentially improving vision and reducing fluid in the retina.
- What could go wrong
- This is a small, early-phase trial with only 50 participants. The drug may not work better than a sham injection, and there are risks from eye injections, such as infection or inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL SEROUS CHORIORETINOPATHY (CSC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.